{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T14:56:21Z","timestamp":1792680981085,"version":"4.5.0"},"reference-count":44,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T00:00:00Z","timestamp":1766016000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>Effective treatment approaches are required for type 2 diabetes mellitus (T2DM) and cardiovascular diseases (CVDs) because these two diseases pose a big health issue for humans. Various medications, but with limitations in their efficacy, are available for the treatment of the above-mentioned diseases, but a drug, empagliflozin, a sodium\u2013glucose cotransporter-2 inhibitor, has shown promising benefits for patients with T2DM and CVD, highlighting the need for a thorough review of its efficacy and safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We searched online databases till 30 June 2024, and a total of 15 trials involving 8296 participants were included in this study. Evaluating the changes in HbA1c was a main concern of our study, while weight-related metrics [such as body weight and Body Mass Index (BMI)], cardiovascular indicators [like systolic blood pressure (SBP), diastolic blood pressure (DBP), changes in left ventricular ejection fraction %, and heart rate], and various laboratory values [including fasting plasma glucose (FPG), C-reactive protein (CRP), hematocrit, estimated glomerular filtration rate] were considered as secondary assessments.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Our study concluded that empagliflozin significantly reduced HbA1c levels [standardized mean difference (SMD)\u00a0=\u00a0\u22120.62, 95% CI\u00a0=\u00a0\u22120.95 to \u22120.30,\n                      <jats:italic toggle=\"yes\">I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      \u00a0=\u00a085%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =\u00a00.0001], indicating improved glycemic control. Additionally, a reduction in body weight was also noted (SMD\u00a0=\u00a0\u22122.32, 95% CI\u00a0=\u00a0\u22123.42 to \u22121.21,\n                      <jats:italic toggle=\"yes\">I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      \u00a0=\u00a054%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.0001). The drug also demonstrated favorable outcomes for secondary endpoints. Meta-regression and subgroup analyses provided insights into the variability of treatment effects across different populations.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>The efficacy of empagliflozin in managing T2DM and CVD is evaluated by this pooled analysis, highlighting great improvement in glycemic control and weight reduction. Further research is needed for empagliflozin\u2019s long-term safety and efficacy across populations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/ms9.0000000000004512","type":"journal-article","created":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T12:01:14Z","timestamp":1766059274000},"page":"1765-1778","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy and safety of SGLT2 inhibitor empagliflozin in T2DM with established cardiovascular disease: a systematic review and meta-analysis of RCTs"],"prefix":"10.1097","volume":"88","author":[{"given":"Omar","family":"Abunada","sequence":"first","affiliation":[{"name":"Department of Medicine, Liaquat University of Medical and Health Sciences, Jamshoro, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farhad","family":"Hassan","sequence":"additional","affiliation":[{"name":"Department of Medicine, Liaquat University of Medical and Health Sciences, Jamshoro, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naresh","family":"Kumar","sequence":"additional","affiliation":[{"name":"Department of Medicine, Liaquat University of Medical and Health Sciences, Jamshoro, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil","family":"Kumar","sequence":"additional","affiliation":[{"name":"Department of Medicine, Liaquat University of Medical and Health Sciences, Jamshoro, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irfan","family":"Majeed","sequence":"additional","affiliation":[{"name":"Department of Medicine, Dow Medical College, Dow University of Health Sciences, Karachi, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kantesh","family":"Batra","sequence":"additional","affiliation":[{"name":"Department of Medicine, Shaheed Mohtarma Benazir Bhutto Medical College Lyari, Karachi, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dheeraj","family":"Kumar","sequence":"additional","affiliation":[{"name":"Department of Medicine, Liaquat University of Medical and Health Sciences, Jamshoro, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepika","family":"Deepika","sequence":"additional","affiliation":[{"name":"Department of Medicine, University Hospitals Birmingham, Birmingham, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muskan","family":"Turesh","sequence":"additional","affiliation":[{"name":"Department of Medicine, Ghulam Muhammad Mahar Medical College, Sukkur, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taimoor","family":"Ashraf","sequence":"additional","affiliation":[{"name":"Department of Medicine, Nishtar Medical University Multan, Multan, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salman","family":"Hyder","sequence":"additional","affiliation":[{"name":"Department of Medicine, Jinnah Postgraduate Medical Centre, Karachi, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keziah Nithiya","family":"Suresh","sequence":"additional","affiliation":[{"name":"Department of Medicine, Thumbay University Hospital, Ajman, UAE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laksh","family":"Kumar","sequence":"additional","affiliation":[{"name":"Department of Medicine, Shaheed Mohtarma Benazir Bhutto Medical College Lyari, Karachi, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumet","family":"Kumar","sequence":"additional","affiliation":[{"name":"Department of Medicine, Shaheed Mohtarma Benazir Bhutto Medical College Lyari, Karachi, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"FNU","family":"Kamlesh","sequence":"additional","affiliation":[{"name":"Department of Medicine, Liaquat College of Medicine and Dentistry, Karachi, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salih Abdella","family":"Yusuf","sequence":"additional","affiliation":[{"name":"Department of Medicine, Hawassa University, Awasa, Ethiopia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,12,18]]},"reference":[{"key":"R1-20260810","doi-asserted-by":"crossref","first-page":"162\u201372","DOI":"10.2337\/dc07-9917","article-title":"Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association","volume":"30","author":"Buse","year":"2007","journal-title":"Diabetes Care"},{"key":"R2-20260810","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jcjd.2019.01.001","article-title":"Angiotensin receptor blockers and angiotensin-converting enzyme inhibitors for the treatment of hypertensive patients with type 2 diabetes mellitus","volume":"44","author":"Kawada","year":"2020","journal-title":"Can J Diabetes"},{"key":"R3-20260810","first-page":"17\u201318","article-title":"Empagliflozin, cardiovascular outcomes, and Mortality in Type 2 diabetes","volume":"13","author":"Zinman","year":"2015","journal-title":"Zeitschrift Fur Gefassmedizin"},{"key":"R4-20260810","doi-asserted-by":"crossref","first-page":"1157\u201366","DOI":"10.1080\/14656566.2020.1751815","article-title":"An evaluation of empagliflozin and it\u2019s applicability to hypertension as a therapeutic option","volume":"21","author":"Herat","year":"2020","journal-title":"Expert Opin Pharmacother"},{"key":"R5-20260810","doi-asserted-by":"crossref","first-page":"17\u201318","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"R6-20260810","doi-asserted-by":"crossref","first-page":"105906","DOI":"10.1016\/j.ijsu.2021.105906","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"88","author":"Page","year":"2021","journal-title":"Int J Surg"},{"key":"R7-20260810","doi-asserted-by":"crossref","DOI":"10.70389\/PJS.100082","article-title":"Transparency In The reporting of Artificial INtelligence \u2013 the TITAN guideline","author":"Agha","year":"2025","journal-title":"Prem J Sci"},{"key":"R8-20260810","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"R9-20260810","doi-asserted-by":"crossref","first-page":"4769","DOI":"10.3390\/jcm11164769","article-title":"Efficacy and safety of empagliflozin in Type 2 diabetes mellitus saudi patients as add-on to antidiabetic therapy: a prospective, open-label, observational study","volume":"11","author":"Althobaiti","year":"2022","journal-title":"J Clin Med"},{"key":"R10-20260810","doi-asserted-by":"crossref","first-page":"4015\u201321","DOI":"10.2337\/dc13-0663","article-title":"Long-term safety and efficacy of empagliflozin, sitagliptin, and metformin","volume":"36","author":"Ferrannini","year":"2013","journal-title":"Diabetes Care"},{"key":"R11-20260810","doi-asserted-by":"crossref","first-page":"417\u201326","DOI":"10.1111\/dom.13909","article-title":"Efficacy and safety of empagliflozin as add-on to insulin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial","volume":"22","author":"Sone","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"R12-20260810","doi-asserted-by":"crossref","first-page":"1154\u201360","DOI":"10.1111\/dom.12185","article-title":"Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia","volume":"15","author":"Rosenstock","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"R13-20260810","doi-asserted-by":"crossref","first-page":"369\u201384","DOI":"10.1016\/S2213-8587(13)70208-0","article-title":"Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial","volume":"2","author":"Barnett","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"R14-20260810","doi-asserted-by":"crossref","first-page":"231\u201344","DOI":"10.1016\/j.kint.2017.06.017","article-title":"Pooled analysis of Phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin","volume":"93","author":"Cherney","year":"2018","journal-title":"Kidney Int"},{"key":"R15-20260810","doi-asserted-by":"crossref","first-page":"2826\u201344","DOI":"10.1007\/s12325-024-02879-w","article-title":"Safety of empagliflozin: an individual participant-level data meta-analysis from four large trials","volume":"41","author":"Wanner","year":"2024","journal-title":"Adv Ther"},{"key":"R16-20260810","doi-asserted-by":"crossref","first-page":"984\u201393","DOI":"10.1111\/dom.12307","article-title":"Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis","volume":"16","author":"Liakos","year":"2014","journal-title":"Diabetes Obes Metab"},{"key":"R17-20260810","doi-asserted-by":"crossref","first-page":"783\u201394","DOI":"10.1111\/dom.12670","article-title":"Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis","volume":"18","author":"Zaccardi","year":"2016","journal-title":"Diabetes Obes Metab"},{"key":"R18-20260810","doi-asserted-by":"crossref","first-page":"761\u201372","DOI":"10.1038\/s41569-020-0406-8","article-title":"SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control","volume":"17","author":"Cowie","year":"2020","journal-title":"Nat Rev Cardiol"},{"key":"R19-20260810","doi-asserted-by":"crossref","first-page":"117\u201328","DOI":"10.1002\/oby.23331","article-title":"SGLT inhibitors on weight and body mass: a meta-analysis of 116 randomized-controlled trials","volume":"30","author":"Cheong","year":"2022","journal-title":"Obesity"},{"key":"R20-20260810","doi-asserted-by":"crossref","first-page":"30\u201336","DOI":"10.1161\/STROKEAHA.110.593434","article-title":"Association between obesity and mortality after acute first-ever stroke","volume":"42","author":"Vemmos","year":"2011","journal-title":"Stroke"},{"key":"R21-20260810","doi-asserted-by":"crossref","first-page":"2111\u201321","DOI":"10.1002\/jcsm.12818","article-title":"Obesity and long-term outcomes after incident stroke: a prospective population-based cohort study","volume":"12","author":"Akyea","year":"2021","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"R22-20260810","doi-asserted-by":"crossref","first-page":"637\u201344","DOI":"10.1007\/s10741-014-9425-z","article-title":"Critical appraisal of the obesity paradox in cardiovascular disease: how to manage patients with overweight in heart failure?","volume":"19","author":"Doehner","year":"2014","journal-title":"Heart Fail Rev"},{"key":"R23-20260810","doi-asserted-by":"crossref","first-page":"565\u201373","DOI":"10.1007\/s11739-024-03532-8","article-title":"Sodium\u2013glucose cotransporter-2 inhibitors in heart failure patients across the range of body mass index: a systematic review and meta-analysis of randomized controlled trials","volume":"19","author":"Adamou","year":"2024","journal-title":"Intern Emerg Med"},{"key":"R24-20260810","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1016\/j.clinthera.2016.08.008","article-title":"Acute pharmacodynamic effects of empagliflozin with and without diuretic agents in patients with type 2 diabetes mellitus","volume":"38","author":"Heise","year":"2016","journal-title":"Clin Ther"},{"key":"R25-20260810","first-page":"2265\u201376","article-title":"Pharmacodynamic effects of single and multiple doses of empagliflozin in patients with type 2 diabetes","volume":"38","author":"Heise","year":"2016","journal-title":"Clin Ther"},{"key":"R26-20260810","doi-asserted-by":"crossref","first-page":"1\u201310","DOI":"10.4061\/2011\/283137","article-title":"The cardiorenal syndrome: making the connection","volume":"2011","author":"Viswanathan","year":"2011","journal-title":"Int J Nephrol"},{"key":"R27-20260810","doi-asserted-by":"crossref","first-page":"644\u201357","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"R28-20260810","doi-asserted-by":"crossref","first-page":"347\u201357","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"R29-20260810","doi-asserted-by":"crossref","first-page":"1232\u201338","DOI":"10.2337\/dc11-1926","article-title":"Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes","volume":"35","author":"Rosenstock","year":"2012","journal-title":"Diabetes Care"},{"key":"R30-20260810","doi-asserted-by":"crossref","DOI":"10.1186\/s13098-022-00951-5","article-title":"The effect of EMPAgliflozin on markers of inflammation in patients with concomitant type 2 diabetes mellitus and Coronary ARtery Disease: the EMPA-CARD randomized controlled trial","volume":"14","author":"Gohari","year":"2022","journal-title":"Diabetol Metab Syndr"},{"key":"R31-20260810","first-page":"844\u201347","article-title":"Increased hematocrit during sodium-glucose cotransporter 2 inhibitor therapy indicates recovery of tubulointerstitial function in diabetic kidneys","volume":"8","author":"Sano","year":"2016","journal-title":"J Clin Med Res"},{"key":"R32-20260810","doi-asserted-by":"crossref","first-page":"3463\u201384","DOI":"10.1007\/s12325-020-01329-7","article-title":"Pooled safety and tolerability analysis of empagliflozin in patients with type 2 diabetes mellitus","volume":"37","author":"Kinduryte Schorling","year":"2020","journal-title":"Adv Ther"},{"key":"R33-20260810","doi-asserted-by":"crossref","first-page":"1299\u2013313","DOI":"10.1016\/j.clinthera.2016.03.031","article-title":"Safety and tolerability of empagliflozin in patients with type 2 diabetes","volume":"38","author":"Kohler","year":"2016","journal-title":"Clin Ther"},{"key":"R34-20260810","doi-asserted-by":"crossref","first-page":"1707\u201326","DOI":"10.1007\/s12325-017-0573-0","article-title":"Safety and tolerability of empagliflozin in patients with type 2 diabetes: pooled analysis of phase i\u2013iii clinical trials","volume":"34","author":"Kohler","year":"2017","journal-title":"Adv Ther"},{"key":"R35-20260810","doi-asserted-by":"crossref","first-page":"1788\u2013801","DOI":"10.1016\/S0140-6736(22)02074-8","article-title":"Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials","volume":"400","author":"Baigent","year":"2022","journal-title":"Lancet"},{"key":"R36-20260810","doi-asserted-by":"crossref","first-page":"1445\u201352","DOI":"10.2337\/dc21-2034","article-title":"Safety of empagliflozin in patients with type 2 diabetes and chronic kidney disease: pooled analysis of placebo-controlled clinical trials","volume":"45","author":"Tuttle","year":"2022","journal-title":"Diabetes Care"},{"key":"R37-20260810","doi-asserted-by":"crossref","first-page":"119\u201329","DOI":"10.1161\/CIRCULATIONAHA.117.028268","article-title":"Empagliflozin and clinical outcomes in patients with type 2 diabetes mellitus, established cardiovascular disease, and chronic kidney disease","volume":"137","author":"Wanner","year":"2018","journal-title":"Circulation"},{"key":"R38-20260810","doi-asserted-by":"crossref","first-page":"4466","DOI":"10.1038\/s41598-018-22658-2","article-title":"Combination of sodium-glucose cotransporter 2 inhibitor and dipeptidyl peptidase-4 inhibitor in type 2 diabetes: a systematic review with meta-analysis","volume":"8","author":"Min","year":"2018","journal-title":"Sci Rep"},{"key":"R39-20260810","doi-asserted-by":"crossref","first-page":"246\u201352","DOI":"10.1590\/1806-9282.65.2.246","article-title":"Use of sodium-glucose cotransporter-2 inhibitors and urinary tract infections in type 2 diabetes patients: a systematic review","volume":"65","author":"Figueiredo","year":"2019","journal-title":"Rev Assoc Med Bras"},{"key":"R40-20260810","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3390\/medicines9120059","article-title":"The incidence and risk factors of urinary tract infection in patients with type 2 diabetes mellitus using SGLT2 Inhibitors: a Real-World Observational Study","volume":"9","author":"Uitrakul","year":"2022","journal-title":"Medicines"},{"key":"R42-20260810","doi-asserted-by":"crossref","first-page":"503\u201314","DOI":"10.1007\/s00592-018-1116-0","article-title":"SGLT-2 inhibitors and the risk of infections: a systematic review and meta-analysis of randomized controlled trials","volume":"55","author":"Puckrin","year":"2018","journal-title":"Acta Diabetol"},{"key":"R43-20260810","doi-asserted-by":"crossref","first-page":"e022577","DOI":"10.1136\/bmjopen-2018-022577","article-title":"Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis","volume":"9","author":"Donnan","year":"2019","journal-title":"BMJ Open"},{"key":"R44-20260810","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.023811","article-title":"National trends in use of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists by cardiologists and other specialties, 2015 to 2020","volume":"11","author":"Adhikari","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"R45-20260810","doi-asserted-by":"crossref","first-page":"1239\u201348","DOI":"10.1007\/s00228-023-03539-8","article-title":"Trends in use of sodium-glucose co-transporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) in Australia in the era of increased evidence of their cardiovascular benefits (2014\u20132022)","volume":"79","author":"Lin","year":"2023","journal-title":"Eur J Clin Pharmacol"}],"container-title":["Annals of Medicine &amp; Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MS9.0000000000004512","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T11:04:14Z","timestamp":1786359854000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MS9.0000000000004512"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,18]]},"references-count":44,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/ms9.0000000000004512","relation":{},"ISSN":["2049-0801"],"issn-type":[{"value":"2049-0801","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,18]]},"assertion":[{"value":"2025-05-29","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-19","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}